40 patents currently held
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Aug 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
7
Ending by 2030
Aug 2028
Next term end
32
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2034 · High confidence
Also notable
Ends Mar 2033 · High confidence
Also notable
Ends Aug 2028 · Medium confidence
Also notable
Ends no later than Mar 2034 · Medium confidence
Also notable
Ends Mar 2030 · High confidence
Also notable
Ends Oct 2033 · High confidence
Also notable
Ends Nov 2033 · High confidence
Also notable
Ends Mar 2034 · High confidence
Compositions Comprising Secretory-Like Immunoglobulins
US 10,221,233
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2034.
Hydrophobic Charge Induction Chromatographic Protein Depleted Solution
US 11,426,680
A family of 7 related applications built on the 2022 grant. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Methods for Purification of ALPHA-1-Antitrypsin and Apolipoprotein A-1
US 8,962,802
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2028.
Treatment and Prevention of Remote Ischemia-Reperfusion Injury
US 10,286,047
Cited by 14 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2034. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Antibody Composition with Altered Fab Sialylation
US 8,632,773
Renewed at every maintenance window since the 2014 grant; no more fees are due before its term ends in 2030.
Process for Enriching Iga
US 9,828,418
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2033.
Combination Therapy Using Immunoglobulin and C1-Inhibitor
US 10,471,142
Granted 2019. Computed term ends 2033.
Method of Purifying Proteins
US 9,534,029
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2034.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 4 to 18, 2027 · next Feb 4
- 1 fee due Mar 5, 2027The maintenance fee for A Blood Coagulation Factor Replacement Product for Use in the Treatment or Prophylaxis of Bleedings (US 11,744,880) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 1 fee due Apr 15, 2027The maintenance fee for Therapeutic Agent for Amniotic Fluid Embolism (US 10,441,631) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
- 1 fee due May 12, 2027The maintenance fee for Combination Therapy Using Immunoglobulin and C1-Inhibitor (US 10,471,142) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 23, 2026
- Nov 11 US 8,119,137 Prevention of Thrombus Formation And/Or Stabilization with Inhibitors of Factor XII or Activated Factor XII · term ended
What they patent
The largest of its 32 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,962,802 | Methods for Purification of ALPHA-1-Antitrypsin and Apolipoprotein A-1 In force · Medium confidence | In force | Medium confidence | |
| US 8,394,768 | Synergistic Therapeutic Use of Prothrombin Complex Concentrates with Fviii Concentrates In force · High confidence | In force | High confidence | |
| US 9,095,564 | Von Willebrand Factor or Factor VIII and Von Willebrand Factor for the Treatment of Coagulopathy Induced by Inhibitors of Thrombocytes In force · High confidence | In force | High confidence | |
| US 10,137,165 | Factor H for the Treatment of Chronic Nephropathies and Production Thereof In force · High confidence | In force | High confidence | |
| US 8,632,773 | Antibody Composition with Altered Fab Sialylation In force · High confidence | In force | High confidence | |
| US 8,603,979 | Von Willebrand Factor or Factor VIII and Von Willebrand Factor for the Treatment of Coagulopathy Induced by Inhibitors of Thrombocytes In force · High confidence | In force | High confidence | |
| US 7,939,632 | Proteolytically Cleavable Fusion Proteins with High Molar Specific Activity In force · High confidence | In force | High confidence | |
| US 9,107,902 | Use of VWF Stabilized Fviii Preparations and of VWF Preparations Without Fviii for Extravascular Administration in the Therapy and Prophylactic Treatment of Bleeding Disorders In force · High confidence | In force | High confidence | |
| US 9,352,016 | Factor XII Inhibitors for the Administration with Medical Procedures Comprising Contact with Artificial Surfaces In force · High confidence | In force | High confidence | |
| US 9,624,307 | Factor XII Inhibitors for the Treatment of Silent Brain Ischemia and Ischemia of Other Organs In force · High confidence | In force | High confidence |
Also on record, not counted in the 40: 4 patents in force now held by others · 49 patents ended · 26 applications pending · 51 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.